Jeremy Sable was diagnosed with eosinophilic esophagitis and eosinophilic gastritis in 1994 at 6 months of age, following significant continued weight loss and “failure to thrive.” Eosinophilic gastrointestinal diseases (EGIDs) were newly classified and amino-based formulas had not yet been approved as a prescription medical food; there was no EGID community. Despite missing many early development milestones, Jeremy graduated cum laude from Virginia Tech in 2016 with a degree in Industrial and Systems Engineering and now works in Washington D.C as a Manager at Deloitte Consulting. Along with his mom, Jeremy has been part of the eosinophil-associated disease (EAD) community, volunteering with American Partnership for Eosinophilic Disorders (APFED), speaking on patient panels, and participating in research studies.

Kathleen Sable is a pioneer in the eosinophilic gastrointestinal disease patient community. Her son Jeremy, now 27, was diagnosed with eosinophilic gastritis and eosinophilic esophagitis in 1994. Since that time, Kathleen has been a passionate advocate, providing patient and caregiver perspective to researchers, lawmakers, pharmaceutical companies, and other stakeholders. Kathleen is a graduate ofVanderbilt University, has an MBA with emphasis in Economic Forecasting and consults with non-profit and small businesses. She has been a long-time, dedicated volunteer for the American Partnership for Eosinophilic Disorders (APFED) and joined the organization’s Board of Directors in 2012.